AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels
Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy
VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first quarter ended March 31, 2018 and provided an overview of business activities.
